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VV3
HOW STABLE ARE SOCIAL PREFERENCE
WEIGHTS FOR EQ-5D: RESULTS FROM A
PARTIAL REPLICATION STUDY
Macran S, Kind P
Outcomes Research Group,York, United Kingdom
In 1993 a national population survey was conducted in
the UK to determine social preference weights for EQ-5D
health states. The survey, conducted as part of the 
Measurement and Valuation of Health (MVH) Project
was based on face-to-face interviews with 3395 respon-
dents who used ranking, VAS rating and time trade-off
(TTO) methods to generate social preference weights. The
TTO weights derived from that survey are widely used 
in economic studies in which EQ-5D is used to measure
outcomes. OBJECTIVES: To test the stability of social
preference weights over time using a partial replication
protocol. METHODS: Face-to-face interviews were con-
ducted with 253 individuals randomly selected from elec-
toral registers in geographically convenient locations. The
protocol varied somewhat from the original MVH study
in that each respondent was asked to value a standard set
of 17 health states. Responses were weighted to achieve
matching with the age/gender mix of the MVH study.
Fieldwork was conducted in 1998. RESULTS: The rank
order of health states was highly similar in the two
surveys. VAS ratings were well approximated in the repli-
cation survey. TTO weights were higher in the second
survey, with fewer states being valued as worse than dead.
The median absolute difference in TTO preference
weights was 0.080. An OLS model used to interpolate
values for unobserved EQ-5D health states yielded 
lower parameter estimates for the extreme levels on 
each dimension in the 1998 data. CONCLUSIONS:
Social preference weights can and do vary over time. An
apparent shift in the value of dead relative to EQ-5D
health states may account for a reduction in the number
of states assigned a negative weight. Although the
absolute value of outcomes may depend upon which set
of weights is used, marginal differences in outcome may
remain unaffected.
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DEVELOPING A PREFERENCE-BASED MEASURE
FOR POSTMENOPAUSAL HEALTH
Brazier JE1, Zoellner YF2, Platts M1,Towers I1
1University of Shefﬁeld, Shefﬁeld, United Kingdom; 2Solvay
Pharmaceuticals, Hannover, Germany
OBJECTIVE: To develop a preference-based index for
(post-) menopausal health, the latter including typical
menopausal symptoms as well as potential side-effects of
their causal treatment, i.e. hormone replacement therapy
(HRT). METHODS: The study had three phases: 1) the
development of a health state classiﬁcation system; 2) a
valuation survey; and 3) the estimation of a model for
valuing all states deﬁned by the system. A menopausal
health state classiﬁcation system with the seven dimen-
sions (QPI-7D) was developed, including hot ﬂushes,
aching joints or muscles, anxious or frightened feelings,
breast tenderness, bleeding, vaginal dryness and undesir-
able androgenic signs. Each dimension contains between
3 and 5 levels and deﬁnes a total of 6075 health states.
A sample of 96 health states was selected for empirical
valuation. These states were valued by a sample of 229
women aged 45 to 60 (37% postmenopausal, 33% on
HRT), randomly selected from 6 general practice lists in
Shefﬁeld, UK. Respondents were asked to complete a time
trade-off (TTO) task for 9 health states (their own plus
8 described states), resulting in an average of 16.5 values
for each health state. RESULTS: Mean health state values
ranged from 0.48 to 0.98. Own health was valued at 0.91
(mean). An additive random effects model of reasonable
ﬁt could be speciﬁed. Decrements for each level of symp-
toms reaching statistical signiﬁcance were estimated. The
general order of decrements (from highest to lowest) is:
aching joints and muscles, bleeding, breast tenderness,
anxious or frightened feelings, vaginal dryness, and
androgenic signs. While “hot ﬂushes” did reach statisti-
cal signiﬁcance in the current HRT user/past sufferer sub-
sample, it did not enhance model ﬁt in the overall sample.
CONCLUSION: This model provides a methodologically
sound and credible algorithm for valuing menopausal
health on the basis of the underlying health state classiﬁ-
cation system, the QPI-7D.
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ACARBOSE FOR THE PREVENTION OF TYPE II
DIABETES IN CANADA: AN ECONOMIC
EVALUATION
Getsios D1, Caro JJ2, Caro I3, Klittich W2, O’Brien JA2
1Caro Research Institute, Hammonds Plains, NS, Canada;
2Caro Research Institute, Concord, MA, USA; 3Caro Research
Institute, Dorval, QC, Canada
OBJECTIVE: To evaluate the cost-effectiveness of acar-
bose for the prevention of type II diabetes in Canadian
patients with impaired glucose tolerance (IGT) compared
to no treatment, metformin, and lifestyle modiﬁcation.
METHODS: A Markov model was developed to estimate
outcomes for patients with IGT. Patients could revert 
to normal glucose tolerance, remain with IGT, develop
diabetes, or die. Baseline transition probabilities were
derived from the STOP-NIDDM study, a placebo-
controlled trial of acarbose for the prevention of type II
diabetes in IGT, and supplemented with data from other
published trials. Direct costs were estimated for Ontario,
in 2000 Canadian dollars. Patients were assumed to
receive therapy for 5 years, and transitions were modeled
over 10 years. Sensitivity analyses covered all inputs.
Costs and outcomes were discounted at 5% per annum.
RESULTS: Over a decade, 542 out of 1000 patients are
expected to develop diabetes in the absence of an active
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intervention. Metformin and acarbose respectively reduce
cases of diabetes by 52 and 74 and reduce costs by $999
and $897 per patient. Acarbose is more effective than
metformin with slightly higher costs and an incremental
cost per life year gained of $1798. An aggressive lifestyle
modiﬁcation program is most effective, but is the most
costly intervention, generating incremental costs com-
pared to no treatment and with an incremental cost of
$9988 per life year gained relative to acarbose. Results
are most sensitive to effectiveness estimates for the inter-
ventions. CONCLUSIONS: These results suggest that the
use of acarbose, metformin, or lifestyle modiﬁcation to
prevent diabetes in people with IGT is cost-effective and
can even lead to cost savings. If an aggressive lifestyle
modiﬁcation can be implemented, it is most effective, but
increases costs by over $1000 per patient relative to
medical therapy. Acarbose is the better option if medica-
tion is used.
DB2
PIOGLITAZONE MONOTHERAPY IS
ASSOCIATED WITH A SIGNIFICANTLY LOWER
INCIDENCE OF CARDIOVASCULAR EVENTS
THAN IS INSULIN THERAPY IN PATIENTS WITH
TYPE 2 DIABETES: A RETROSPECTIVE
PROPENSITY-ADJUSTED COHORT ANALYSIS
Rajagopalan R1, Xu Y1, Rosenson RS2, Khan M1, Murray FT1
1TAKEDA Pharmaceuticals North America, Inc, Lincolnshire,
IL, USA; 2The Feinberg School of Medicine, Chicago, IL, USA
OBJECTIVE: We examined cardiovascular risk by com-
paring pioglitazone (PIO) therapy with insulin (INS)
therapy in a large database in which medical, drug, and
laboratory information was collected using electronic
case report forms. METHODS: Adult patients with type
2 diabetes mellitus were included if active in the database
after 1999, and if no cardiovascular events were present
in the history before baseline. Patients on monotherapy
(PIO or INS) or in combination with sulfonylureas were
included. To avoid selection bias and increase precision
on the estimated treatment effect, we used propensity
scoring, stratiﬁed matching methods, and logistic regres-
sion analysis. Baseline demographics and clinical charac-
teristics such as disease duration, comorbidities, medical
therapies, and treatment duration were used to calculate
the propensity score. RESULTS: A total of 515 patients
taking PIO alone or with sulfonylureas were compared
with 2554 patients taking INS alone or in combination
with sulfonylureas. The treatment period ranged from
6–36 months. The crude cardiac event rate in the PIO
group was 5.44%, compared with 10.96% in the INS
group (P < 0.003), and the hazard ratio was 0.499 for
PIO (95% conﬁdence interval [CI]: 0.315, 0.791; P <
0.003). When patients on monotherapy alone were com-
pared, the crude event rates were 3.86%, compared with
11.32% in the INS group (P < 0.002), and the hazard
ratio was 0.346 for PIO (95% CI: 0.172, 0.694; P <
0.003). The signiﬁcant risk reduction in the PIO groups
could not be explained by baseline clinical or labora-
tory measurements. CONCLUSION: In a retrospective
propensity-matched cohort analysis in patients with type
2 diabetes, patients taking PIO had a signiﬁcantly lower
hazard for a cardiovascular event over a period of 6–36
months than those taking insulin.
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COST-EFFECTIVENESS OF ROSIGLITAZONE-
METFORMIN COMBINATION IN OVERWEIGHT
PATIENTS WITH TYPE 2 DIABETES IN
GERMANY
Shearer A1, Bagust A1, Schoeffski O2, Reitberger U3,
Goertz A4, Behrens M5
1University of York,York, United Kingdom; 2University
Erlangen-Nuremberg, Nuremberg, Germany; 3Kendle
International Inc, Munich, Germany; 4GlaxoSmithKline, Munich,
Germany; 5GlaxoSmithKline, Uxbridge, United Kingdom
OBJECTIVES: Guidelines in Germany recommend use 
of Rosiglitazone in combination with Metformin for 
treatment of overweight and obese patients (BMI ≥ 25)
with Type 2 diabetes when Metformin monotherapy is 
no longer effective in maintaining glycaemic control. We
assess the cost-effectiveness of this strategy compared to
combination therapy with Glibenclamide. METHODS:
DiDACT, an established long-term economic model of
Type 2 diabetes, was adapted for clinical practice and
health care ﬁnancing rules in Germany. The model was
calibrated using CODE-2 study data and national statis-
tics. The perspective is that of the sickness funds, 
and includes all hospital care, physician consultations, 
medications, rehabilitation, physiotherapy, foot care and
sick leave. The model was used to simulate treatment 
histories for a mixed incident cohort of 1000 overweight
preobese patients (mean BMI = 26). Following failure 
of glycaemic control with Metformin alone, combination
therapy adding Rosiglitazone was compared to adding
Glibenclamide. The threshold for switching therapies was
7% HbA1c. In line with national guidelines, costs were
discounted at 5%. RESULTS: The model predicts that
adding Rosiglitazone (4mg titrated to 8mg daily) to 
Metformin produces better glycaemic control in most
patients, and extends viability of combination therapy by
8.5 years before requiring insulin. This is projected to gen-
erate 444 additional QALYs in a cohort of 1000 newly
diagnosed overweight patients over their lifetime. The
additional QALYs comprise 245 (55%) from better sur-
vival and 199 (45%) from delaying insulin and reduced
or delayed complications. Net cost increases are modest
since additional costs of Rosiglitazone are partly offset by
savings from delaying insulin therapy. After 20 years, 
the incremental cost-effectiveness ratio is €2730 per 
QALY gained (undiscounted) or €1804 (discounted).
CONCLUSIONS: Use of Rosiglitazone in combination
with Metformin to improve glycaemic control and delay
use of insulin in overweight patients is highly cost-
effective in Germany when compared to Metformin +
Glibenclamide.
